SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Intra-Cellular Therapies, Inc. (ITCI) , forward earnings yield 3.27%. PEG 0.56 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 30.6
- PEG Ratio 0.56 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $132.00 (+0.1% upside) — modest upside expected.
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ITCI
Valuation Multiples
P/E (TTM)0.0
Forward P/E30.6
PEG Ratio0.56
Forward PEG0.56
P/B Ratio0.00
P/S Ratio19.97
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.72
Forward EPS (Est.)$4.31
Book Value / Share$0.00
Revenue / Share$6.60
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield3.27%
Dividend Yield0.00%
Analyst Target$132.00 (+0.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-2.91 |
$91.36K |
$-104.79M |
-114698.5% |
| 2016 |
$-2.69 |
$330.7K |
$-116.43M |
-35205.8% |
| 2017 |
$-2.12 |
$245.84K |
$-97.77M |
-39771.6% |
| 2018 |
$-2.84 |
$0.00 |
$-155.13M |
- |
| 2019 |
$-2.68 |
$60.61K |
$-147.72M |
-243713.7% |
| 2020 |
$-3.23 |
$22.53M |
$-227.01M |
-1007.5% |
| 2021 |
$-3.50 |
$81.71M |
$-284.13M |
-347.7% |
| 2022 |
$-2.72 |
$249.13M |
$-256.26M |
-102.9% |
| 2023 |
$-1.46 |
$464.37M |
$-139.67M |
-30.1% |
| 2024 |
$-0.72 |
$680.85M |
$-74.68M |
-11% |
